Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/58775
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Khoo, J. | - |
dc.contributor.author | Rayner, C. | - |
dc.contributor.author | Jones, K. | - |
dc.contributor.author | Horowitz, M. | - |
dc.date.issued | 2009 | - |
dc.identifier.citation | Therapeutics and Clinical Risk Management, 2009; 5(1):683-698 | - |
dc.identifier.issn | 1176-6336 | - |
dc.identifier.issn | 1178-203X | - |
dc.identifier.uri | http://hdl.handle.net/2440/58775 | - |
dc.description.abstract | The advent of ‘incretin-based therapies’ – GLP-1 agonists and dipeptidyl-peptidase-4 inhibitors – which result in improvements in glycemic control comparable to those with existing oral hypoglycemic agents, and potentially improve cardiovascular and pancreatic β-cell function, represents a major therapeutic advance in the management of type 2 diabetes. Gastrointestinal adverse effects occur commonly with GLP-1 agonists, and rarely with DPP-4 inhibitors, but are dose-dependent and usually transient. The low risk of hypoglycemia, and beneficial or neutral effects on body weight, render GLP-1 agonists and DPP-4 inhibitors suitable alternatives to insulin secretagogues and insulin in overweight and elderly patients. Incretin-based therapies also improve quality of life in patients with type 2 diabetes, and may be cost-effective in the long term. | - |
dc.description.statementofresponsibility | Joan Khoo, Christopher K Rayner, Karen L Jones, and Michael Horowitz | - |
dc.language.iso | en | - |
dc.publisher | Dove Medical Press Ltd. | - |
dc.rights | © 2009 Khoo et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited. | - |
dc.source.uri | http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2731024/pdf/tcrm-5-683.pdf | - |
dc.subject | incretin | - |
dc.subject | type 2 diabetes | - |
dc.subject | therapy | - |
dc.subject | GLP‑1 DPP‑4 | - |
dc.title | Incretin-based therapies: New treatments for type 2 diabetes in the new millennium | - |
dc.type | Journal article | - |
pubs.publication-status | Published | - |
dc.identifier.orcid | Rayner, C. [0000-0002-5527-256X] | - |
dc.identifier.orcid | Horowitz, M. [0000-0002-0942-0306] | - |
Appears in Collections: | Aurora harvest 5 Medicine publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.